UK-based biotech Avacta Group plc plans to action its proprietary Affimer and pre|CISION platforms in a wide range of disease areas – creating products that are easier to manufacture than traditional antibody therapies.
Avacta Pursues Combination Therapy Approach Targeting Solid Tumors
Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.
More from C-Suite Speaks
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
More from Leadership
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.